MEDP:NSD-Medpace Holdings Inc (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 361.29

Change

+6.64 (+1.87)%

Market Cap

USD 10.90B

Volume

0.25M

Analyst Target

USD 118.40
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

-0.97 (-0.19%)

USD 41.20B
ICLR ICON PLC

+9.91 (+3.39%)

USD 24.84B
ILMN Illumina Inc

+0.76 (+0.58%)

USD 20.58B
NTRA Natera Inc

-0.11 (-0.09%)

USD 15.65B
EXAS EXACT Sciences Corporation

+1.22 (+1.79%)

USD 11.40B
RDNT RadNet Inc

+0.30 (+0.45%)

USD 5.01B
SHC Sotera Health Co

+0.08 (+0.48%)

USD 4.76B
NEOG Neogen Corporation

+0.37 (+2.19%)

USD 3.50B
GH Guardant Health Inc

-0.01 (-0.04%)

USD 3.30B
TWST Twist Bioscience Corp

-0.65 (-1.36%)

USD 2.75B

ETFs Containing MEDP

UIQI:F UBS (Irl) Fund Solutions .. 96.30 % 0.00 %

-1.64 (-1.09%)

USD 0.31B
UIQI:XETRA UBSs plc - MSCI AC Asia E.. 96.30 % 0.00 %

-0.74 (-1.09%)

USD 0.31B
AJEUAS:SW UBS (Irl) Fund Solutions .. 96.30 % 0.00 %

N/A

N/A
LCPE:LSE Ossiam Shiller Barclays C.. 7.75 % 0.00 %

-367.50 (-1.09%)

USD 0.17B
DXSH:XETRA Xtrackers - Stoxx Europe .. 4.82 % 0.00 %

-0.92 (-1.09%)

USD 0.03B
L6EW:LSE Ossiam Stoxx Europe 600 E.. 4.65 % 0.00 %

-70.00 (-1.09%)

USD 0.11B
S6EW:PA Ossiam Stoxx Europe 600 E.. 4.65 % 0.00 %

-0.44 (-1.09%)

USD 0.11B
OSX6:XETRA Ossiam Stoxx Europe 600 E.. 4.65 % 0.00 %

-0.42 (-1.09%)

USD 0.16B
S6EW:SW Ossiam STOXX® Europe 600.. 4.65 % 0.00 %

N/A

USD 0.11B
XCLN:CA iShares Global Clean Ener.. 4.06 % 0.00 %

N/A

CAD 9.72M
IQQH:XETRA iShares Global Clean Ener.. 4.05 % 0.00 %

-0.01 (-1.09%)

USD 3.34B
INRG:SW iShares Global Clean Ener.. 4.05 % 0.00 %

N/A

USD 2.92B
INRE:PA iShares Global Clean Ener.. 4.05 % 0.00 %

-0.06 (-1.09%)

N/A
ICLN iShares Global Clean Ener.. 4.05 % 0.46 %

-0.05 (-1.09%)

USD 2.12B
ZCLN:CA BMO Clean Energy Index ET.. 4.02 % 0.00 %

+0.15 (+-1.09%)

CAD 0.07B
AMID Argent Mid Cap ETF 3.71 % 0.00 %

-0.19 (-1.09%)

N/A
EUDV:PA SSgA SPDR ETFs Europe I P.. 3.71 % 0.00 %

-0.02 (-1.09%)

USD 0.98B
SPYW:XETRA SPDR S&P Euro Dividend Ar.. 3.71 % 0.00 %

-0.03 (-1.09%)

USD 0.97B
EUDI:LSE SPDR® S&P Euro Dividend .. 3.67 % 0.00 %

+0.01 (+-1.09%)

USD 1.00B
EUDV:LSE SPDR® S&P Euro Dividend .. 3.67 % 0.00 %

-0.05 (-1.09%)

USD 0.99B
PTH Invesco DWA Healthcare Mo.. 3.64 % 0.60 %

+0.25 (+-1.09%)

USD 0.15B
EUDV:SW SPDR® S&P Euro Dividend .. 3.48 % 0.00 %

-0.01 (-1.09%)

N/A
VCLN Virtus Duff & Phelps Clea.. 3.40 % 0.00 %

+0.21 (+-1.09%)

USD 5.06M
UTIL:LSE SPDR® MSCI Europe Utilit.. 2.86 % 0.00 %

-1.59 (-1.09%)

USD 0.15B
STU:PA SPDR® MSCI Europe Utilit.. 2.86 % 0.00 %

-1.68 (-1.09%)

USD 0.15B
SPYU:XETRA SPDR® MSCI Europe Utilit.. 2.86 % 0.00 %

-1.76 (-1.09%)

USD 0.16B
STUX:SW SPDR® MSCI Europe Utilit.. 2.86 % 0.00 %

-1.88 (-1.09%)

USD 0.15B
ASRS:F BNP Paribas Easy ECPI Glo.. 2.67 % 0.00 %

N/A

N/A
HYDRO:PA BNP Paribas Easy ECPI Glo.. 2.67 % 0.00 %

+0.03 (+-1.09%)

N/A
HYDUS:PA BNP Paribas Easy ECPI Glo.. 2.67 % 0.00 %

+0.01 (+-1.09%)

N/A
JSMD Janus Henderson Small/Mid.. 2.16 % 0.50 %

+0.04 (+-1.09%)

USD 0.37B
EMEC:XETRA BNP Paribas Easy ECPI Cir.. 2.14 % 0.00 %

-0.13 (-1.09%)

USD 0.62B
REUSE:PA BNP Paribas Easy ECPI Cir.. 2.14 % 0.00 %

-0.13 (-1.09%)

N/A
REUSD:PA BNP Paribas Easy ECPI Cir.. 2.14 % 0.00 %

-0.03 (-1.09%)

N/A
QSML:AU VanEck MSCI International.. 1.45 % 0.00 %

+0.18 (+-1.09%)

N/A
RFG Invesco S&P MidCap 400® .. 0.00 % 0.35 %

+0.05 (+-1.09%)

N/A
INFR ClearBridge Sustainable I.. 0.00 % 0.47 %

-0.17 (-1.09%)

USD 8.31M
SMLF iShares MSCI USA Small-Ca.. 0.00 % 0.30 %

+0.03 (+-1.09%)

N/A
INRG:LSE iShares Global Clean Ener.. 0.00 % 0.00 %

-4.25 (-1.09%)

N/A
S6EW:LSE Ossiam Stoxx Europe 600 E.. 0.00 % 0.00 %

-0.48 (-1.09%)

N/A
JELS:LSE 0.00 % 0.00 %

N/A

N/A
IQQH:F iShares Global Clean Ener.. 0.00 % 0.00 %

+0.05 (+-1.09%)

N/A
OSX6:F Ossiam Lux - Ossiam Stoxx.. 0.00 % 0.00 %

N/A

N/A
SPYU:F SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

-0.82 (-1.09%)

N/A
SPYW:F SPDR S&P Euro Dividend Ar.. 0.00 % 0.00 %

+0.10 (+-1.09%)

N/A
IBBJ 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 17.86% 76% C+ 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.86% 76% C+ 77% C+
Trailing 12 Months  
Capital Gain 41.85% 82% B 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 41.85% 82% B 83% B
Trailing 5 Years  
Capital Gain 325.05% 97% N/A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 325.05% 97% N/A 95% A
Average Annual (5 Year Horizon)  
Capital Gain 45.41% 80% B- 89% A-
Dividend Return 45.41% 80% B- 89% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 39.81% 70% C- 46% F
Risk Adjusted Return 114.06% 100% F 98% N/A
Market Capitalization 10.90B 88% B+ 93% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.